Precigen, Inc.
$4.11
▲
0.25%
2026-04-21 08:49:01
precigen.com
NMS: PGEN
Explore Precigen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.45 B
Current Price
$4.11
52W High / Low
$5.46 / $1.23
Stock P/E
—
Book Value
$0.06
Dividend Yield
—
ROCE
-90.19%
ROE
-5.72%
Face Value
—
EPS
$-1.37
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
160
Beta
1.12
Debt / Equity
470.04
Current Ratio
3.09
Quick Ratio
2.83
Forward P/E
-18.91
Price / Sales
152.04
Enterprise Value
$1.47 B
EV / EBITDA
-14.24
EV / Revenue
152.08
Rating
Buy
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 2. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
| 3. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 4. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 5. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 6. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 7. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 4.57 M | 2.92 M | 0.86 M | 1.34 M | 1.19 M | — |
| Operating Profit | -21.67 M | -34.48 M | -27.86 M | -22.6 M | -22.74 M | — |
| Net Profit | -23.5 M | -146.34 M | -26.64 M | -54.15 M | -19.73 M | — |
| EPS in Rs | -0.07 | -0.41 | -0.08 | -0.15 | -0.06 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.68 M | 3.92 M | 6.22 M | 26.91 M |
| Operating Profit | -106.6 M | -94.7 M | -88.92 M | -74.61 M |
| Net Profit | -250.64 M | -126.23 M | -95.9 M | 28.32 M |
| EPS in Rs | -0.71 | -0.36 | -0.27 | 0.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 155.5 M | 145.27 M | 151.04 M | 215.98 M |
| Total Liabilities | 134.59 M | 106.75 M | 32.55 M | 89.72 M |
| Equity | 20.91 M | 38.51 M | 118.5 M | 126.26 M |
| Current Assets | 115.23 M | 102.41 M | 68.75 M | 118.16 M |
| Current Liabilities | 37.31 M | 21.52 M | 22.98 M | 78.64 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -87.83 M | -68.17 M | -66.93 M | -65.05 M |
| Investing CF | -1.53 M | -20.71 M | -3.09 M | 226.42 M |
| Financing CF | 90.05 M | 110.58 M | 29.59 M | -155.29 M |
| Free CF | -89.83 M | -76.76 M | -68.47 M | -69.97 M |
| Capex | -2 M | -8.58 M | -1.54 M | -4.92 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -36.95% | -76.87% | — | — |
| Earnings Growth % | -31.63% | -438.68% | — | — |
| Profit Margin % | -3216.18% | -1540.63% | 105.23% | — |
| Operating Margin % | -2412.87% | -1428.48% | -277.25% | — |
| Gross Margin % | -8.71% | 1.7% | 76.44% | — |
| EBITDA Margin % | -3146.39% | -1433.35% | -231.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.